Connor Downs

Researchers are evaluating the drug levels, efficacy, and safety of Deucravacitinib in children aged 4 to less than 18 years with moderate to severe plaque psoriasis. The study includes two age groups children 12 to less than 18 years Cohort 1 and children 4 to less than 12 years Cohort 2. The purpose is to understand how the drug works in these age groups and to assess its safety and effectiveness. A long-term extension lasting up to 5 years will observe the ongoing safety and tolerability in participants who complete the initial study phases. The study has two parts for each cohort. Part A focuses on measuring drug levels to select two dose levels to test further. Part B then compares the safety and effectiveness of these two doses in the pediatric participants. Participants may receive Deucravacitinib at a standard dose, a half-standard dose, or a placebo. The long-term extension period follows participants who finish Parts A or B to monitor long-term effects and safety. During the study, participants will have regular assessments including psoriasis severity scores such as the Psoriasis Area and Severity Index PASI and Physicians Global Assessment sPGA. Safety is monitored through adverse event tracking, laboratory tests, and growth measurements like body weight, height, and sexual maturation stages. These evaluations occur up to 316 weeks, ensuring thorough observation of treatment impact and participant health over time.